Summary
Amir Taheri-ghahfarokhi is a genome-editing leader and co-founder serving as CSO at Immitra Bio, driving in-vivo editing programs aimed at curative therapies for hematopoietic stem cells. With nine years of hands-on experience across pharma and biotech, he combines deep molecular biology and CRISPR expertise with practical productization—taking projects from proof-of-concept to lead optimization. Previously he built patented discovery pipelines, novel VLP production methods that slashed timelines, and achieved in-vivo Prime Editing benchmarks using proprietary delivery. He also led bioinformatics efforts at AstraZeneca, developing off-target prediction algorithms and NGS pipelines that underpinned target validation and guide design. Based in Schlieren, Zurich, Amir blends wet-lab innovation with cloud-enabled data engineering, including AWS platforms and sequencing analytics tools. Colleagues describe him as a scientist-operator who translates cutting-edge discovery into reproducible preclinical programs.
9 years of coding experience
6 years of employment as a software developer
Bachelor of Science (B.Sc.), Animal Sciences, Bachelor of Science (B.Sc.), Animal Sciences at University of Kurdistan, Sanandaj
Doctor of Philosophy (Ph.D.), Molecular Genetics, Doctor of Philosophy (Ph.D.), Molecular Genetics at Ferdowsi University of Mashhad
Persian, English